

DAFTAR PUSTAKA

1. Saygin C, Carraway HE. Review : Emerging therapies for acute myeloid leukemia. *Journal of Hematology and Oncology*.2017; 10(93): 1-12.
2. Enright H, Browne P. Understanding acute myeloid leukaemia. *Irish Cancer Society*. 2016: 15-16.
3. Sukardja DG. *Onkologi klinik*. Edisi 2. Surabaya : Airlangga University Press. 2000.
4. Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK, dkk. Diagnosis and management of acute myeloid leukemia in adults : recommendations from an international expert, on behalf of the European LeukemiaNet. *Blood*. 2010; 11: 453-74.
5. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) : Acute Myeloid Leukemia version. 2. National Comprehensive Cancer Network. 2014.
6. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) : Acute Myeloid Leukemia version. 3. National Comprehensive Cancer Network. 2017.
7. Schlenk RF. Review Articles : Post-remission therapy for acute myeloid leukemia. Germany: Department of Internal Medicine III, University Hospital Ulm. *Hematologica*. 2014; 99(11): 1663-1668.
8. Kline JM, Miller CA, Griffith M, dkk. Association between mutation clearance after induction therapy and outcomes in acute myeloid leukemia. *JAMA*. 2015; 314(8): 811-822.
9. Rassi FE, Arellano M. Update on optimal management on acute myeloid leukemia. *Clinical Medicine Insights : Oncology*. 2013; 7: 181-197.
10. Rashidi A, Walter RB, Tallman MS, Appelbaum FR, Dipierro JF. Maintenance therapy in acute myeloid leukemia : an evidence-based review of randomized trials. *Blood*. 2016; 128(6): 763-773.
11. Sjakti HA, Gatot D, Windiastuti E. Hasil pengobatan leukemia mieloblastik akut pada anak. *Sari Pediatri*. 2012; 14(1).

12. Instalasi Rekam Medik RSUP Dr. M Djamil Padang. Pasien leukemia mieloblastik akut tahun 2015-2017. Rekam Medik RSUP Dr. M Djamil Padang
13. Dorland WAN. Kamus saku kedokteran dorland. Edisi ke 28. Jakarta: Buku Kedokteran EGC; 2014: 1194.
14. Rofinda ZD. Kelainan hemostasis pada leukemia. Jurnal Kesehatan Andalas. 2012; 1(2): 68-72.
15. Yuliana. Perkembangan terapi leukemia mieloid akut. CDK-250.2017; 44(3): 216-220.
16. Leukemia Foundation. Acute myeloid leukemia : a guide for patients and families. 2015.
17. Arismendy JP, Arroyave JC, Rothlisberger S. Review : molecular biomarker in acute myeloid leukemia. Blood Review. 2017; 31; 63-76.
18. WHO.(2012).GLOBOCAN 2012 : Estimated cancer incidence, mortality, and prevalence worldwide in 2012. www.globocan.iarc.fr - Diakses 25 Agustus 2017.
19. American Cancer Society. (2017). What are the key statistics about acute myeloid leukemia. American Cancer Society. <http://www.cancer.org/cancer/acute-myeloid-leukemia/about/key-statistics.html> - Diakses 25 Agustus 2017.
20. American Cancer Society. (2017). Cancer facts and figures 2017. <http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-048738.pdf>. - Diakses 25 Agustus 2017.
21. Kementerian Kesehatan RI. Riset Kesehatan Dasar 2013. 2013.
22. Kouchkovsky ID, Abdul-Hay M. Review acute myeloid leukemia : a comprehensive review 2016 update. Blood Cancer Journal. 2016; e441(6): 4-1.
23. Wetzler M, Byrd JC, Bloomfield CD. Acute and chronic myeloid leukemia. In : Longo DL, editor. Harrison's Hematology and Oncology. 3rd ed. New York : McGraw-Hill; 2016: 171-166.

24. Cortes EJJ, Ravandi F, O'Brien S, Kantarjian H. Targeted therapies in hematology and their impact on patient care : chronic and acute myeloid leukemia. *Semin Hematol. National Institute of Health.* 2013; 50(4): 271-283.
25. Stein EM, Tallman MS. Remission induction in acute myeloid leukemia. *International Journal of Hematology.* 2012; 96(2): 164-170.
26. Hoffbrand AV, Moss PAH, Sandra F, editors. *Kapita Selektta Hematologi.* Edisi ke-6. Jakarta : EGC ; 2013: 150-166.
27. Katzung BG, Masters SB, Trevor AJ. *Basic and Clinical Pharmacology.* 13th ed. New York : McGraw-Hill; 2014.
28. Seiter K, Talavera F. (2017). Acute myelogenous leukemia. <http://emedicine.medscape.com/article/197802-treatment> Diakses tanggal 19 Oktober 2017.
29. Tholl F, Schelink RF, Heuser M, Ganser A. How i treat refractory and early relapse acute myeloid leukemia. *Blood.* 2015; 126(3): 319.
30. Eastern Cooperative Oncology Group ;ECOGperformance status. <http://ecog-acrin.org/resources/ecog-performance-status> - Diakses 4 November 2017.
31. Crooks V, Waller S, dkk. The use of the karnofsky permorfance scale in determining outcomes and risk in geriatric outpatients. 1991; 46: 139-144.
32. Almeida AM, Ramos F. Acute myeloid leukemia in older adults. *Leukemia Research Reports.* 2015: 1-7.
33. Ramos F, Thepot S, Pleyer L, dkk. Azaticidine frontline therapy for unfit acute myeloid leukemia patients : clinical use and outcome prediction. *Leukemia Research.* 2015; 39(3): 296-306.
34. Walter RB, Estey EH. Consice Review : Management of older or unfit patients with acute myeloid leukemia. *Leukemia.* 2015; 29: 770-775.
35. Walter RB, Taylor RL, Gardner KM, Dorcy KS, Vaughn JE, Estey EH. Outpatient management following intensive induction or salvage chemotherapy for acute myeloid leukemia. *Clinical Advances Hematology and Oncology Journal.* 2013; 11(9): 571-577.

36. Kurnianda J. Leukemia mieloblastik akut. Dalam : Sudoyo AW, Setiyohadi B, Alwi I, Simadibrata M, Setiati S, editors. Buku Ajar Ilmu Penyakit Dalam Jilid 2. Edisi 6. 2015. Jakarta : Balai Penerbit FK UI; 2671-2677.
37. Rasjidi I. Buku ajar onkologi klinis. Edisi 2. Surabaya : Airlangga University Press. 2000.
38. Chabner BA, Longo DL. Cancer chemotherapy and biotherapy : principles and practices. 4th edition. New York : McGraw-Hill; 2006.
39. Yudhani, RD. Continuing professional development : farmakogenomik dan terapi kanker. CDK-217. 2014; 41(6): 412-415.
40. American Cancer Society. (2016). Treating acute myeloid leukemia : general treatment information about acute myeloid leukemia.
41. Dohner H, Estey H, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from international expert panel. Blood. 2017; 129(4): 424-440.
42. Simajorang C. Perbedaan ketahanan hidup 5 tahun pasien leukemia limfoblastik akut dan leukemia mieloblastik akut di Rumah Sakit Kanker Dharmais Jakarta tahun 1997-2008 (dissertation). Jakarta : Universitas Indonesia; 2012.
43. Arber DA, Orazi A, Hassirjian R, et al. The 2016 revision to The World Health Organization classification of myeloid neoplasm and acute leukemia. Blood. 2016; 127(20): 2391-2405.
44. Walter RB, Kantarjian Mh, et al. Effects of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined eastern cooperative oncology group, southwest oncology group, and M.D Anderson cancer study. 2010; 28(10): 1766-1771.
45. Yu MG, Zheng HY. Acute myeloid leukemia : advancements in diagnosis and treatment. Chinese Medical Journal. 2017; 130(2): 211-216.
46. Klepin HD, Geiger AM, Tooze JA, et al. Geriatric assessment predict survival for older adults receiving induction chemotherapy for acute myelogenous leukemia. Blood. 2013; 121(21): 4287-4294.
47. Medeiros BC, Hoang SS, Hurst D, Hoang KQ, Momin F, Reyes C. Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in The United States. Ann Hematol. 2015; 94: 1127-1138.

48. Bello C, Yu D, Komrokji RS, et al. Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome. *Moffitt Cancer*. 2011; 1463-1469.
49. Chen CC, Yang CF, Yang MH, et al. Pretreatment prognostic factors and treatment outcomes in elderly patients with de novo acute myeloid leukemia. *Annals of Oncology*. 2005; 16: 1366-1373.
50. Nurbaety B, Perwitasari DA, Andalusia R. Penggunaan antibiotik pada pasien leukemia akut dewasa dengan *febrile neutropenia* setelah pemberian kemoterapi agresif di RS Kanker Dharmais Jakarta. *Media Farmasi*. 2014; 11(2): 179-188.
51. Fircanis S, Merriam P, Khan N, Castillo JJ. The relation between cigarette smoking and risk of acute myeloid leukemia : an updated meta-analysis of epidemiological studies. *American Journal of Hematology* 2014; 89(8): 125-132.
52. Maurillo L, Buccisano F, Principe MI, et al. Treatment of acute myeloid leukemia with 20-30% bone marrow blasts. *Mediterranean Journal of Hematology and Infectious Disease*. 2013; 5(1)
53. Buchner T, Berdel WE, Haferlach C, et al. Age-related risk profile and chemotherapy dose response in acute myeloid leukemia : a study by german acute myeloid leukemia cooperative group. *American Society of Clinical Oncology*. 2009; 27(1): 61-68.
54. Vey N, Coso D, Bardou VD, et al. The benefit of induction in patients age \geq 75 years. *American Cancer Society*. 2004; 101(2): 325-330.
55. Tasaki T, Yamauchi T, Matsuda Y, et al. The response to induction therapy is crucial for the treatment outcomes of elderly patients with acute myeloid leukemia: single institution experience. *Anticancer Research*. 2014; 34: 5631-
56. Goldstone AH, Burnett AK, Wheatley K, Smith AG, Hutchinson M, Clark RE. Attempts to improve treatment outcomes in acute myeloid leukemia in older patients: the results of the United Kingdom medical research council AML 11 trials. *Blood*. 2001; 98(5): 1302-1309.
57. Anderson JE, Kopecky KJ, Willman CL, et al. Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin : a Southwest oncology group study. *Blood*. 2002; 100(12): 3869-3876.

58. Baz R, Rodriguez C, Fu AZ, et al. Impact of remission induction chemotherapy on survival in older adults with acute myeloid leukemia. *American Cancer Society*. 2007; 110(8): 1752-1758.
59. Appelbbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. *Blood*. 2006; 107(9): 3481-3485.
60. Deschler B, Lubbert M. Acute myeloid leukemia : epidemiology and etiology. *Cancer*. 2006; 107(9): 2009-2105.
61. Amin Hm, Yang Y, Shen Y, Estey EH, Giles FJ, Pierce FA, dkk. Having a higher blast percentage in circulation than bone marrow: clinical implications in myelodysplastic syndrome and acute lymphoid and myeloid leukemias. *Leukemia*. 2005; 19: 1567-1572.
62. Hasserjia RP, Campigotto F, Klepeis V, Fu Bin, Wang SA, Byeso-Ramos C, dkk. De novo acute myeloid leukemia with 20-29% blast is less aggressive than acute myeloid leukemia with $\geq 30\%$ blasts in older adults : a bone marrow pathology group study. *American Journal of Hematology*. 2014; 89(11): 193-198.
63. Brandwein JM, Gupta V, Schuh AC, et al. Predictors of response to reinduction chemotherapy for patients with acute myeloid leukemia who do not achieve complete remission with frontline induction therapy. *American Journal of Hematology*. 2007: 54-57.
64. Thein MS, Ershler WB, Jemal A, Yates JW, Baer MR. Outcome of older patients with acute myeloid leukemia. *Cancer*. 2013: 2720-2726.
65. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults : incidence and treatment. *Journal of National Cancer Institute*. 1999; 91(19): 1616-1630.
66. Porcu P, Cripe LD, Bhatia S. Hiperleukocytic leukemia and leukostasis : a review of pathophysiology, clinical presentation and management. *Leuk Lymphoma*. 2000; 39(2): 1-18.
67. Ma E, Bonthapally V, Chawla A, et al. An Evaluation of treatment patterns and outcomes in elderly patients newly diagnosed with acute myeloid leukemia. *Clinical Lymphoma, Myeloma, and Leukemia*. 2016; 16(11): 625-635.
68. Zhang Q, Dai K, Bi L, et al. Pretreatment platelet count predicts survival outcome of patients with de novo non-M3 acute myeloid leukemia. *PeerJ*. 2017; 39: 1-13.

69. Yoon JH, Cho BS, Kim HJ, et al. Outcomes of elderly de novo acute myeloid leukemia treated by a risk-adapted approach based on age, comorbidity, and performance status. *American Journal of Hematology*. 2013; 88: 1074-1081.
70. Wang ES. Treating acute myeloid leukemia in older adults. *American Society of Hematology*. 2014: 14-18.
71. Grimwade D, Walker H, Harrison G. Predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia. *Blood*. 2001; 98(5): 1312-1320.

